KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Equity (2016 - 2025)

CRISPR Therapeutics AG's Return on Equity history spans 10 years, with the latest figure at 0.3% for Q4 2025.

  • For Q4 2025, Return on Equity fell 32.0% year-over-year to 0.3%; the TTM value through Dec 2025 reached 0.3%, down 32.0%, while the annual FY2025 figure was 0.3%, 32.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.3% at CRISPR Therapeutics AG, down from 0.05% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.2% in Q2 2021 and bottomed at 0.34% in Q4 2022.
  • The 5-year median for Return on Equity is 0.04% (2024), against an average of 0.08%.
  • The largest annual shift saw Return on Equity skyrocketed 39bps in 2021 before it tumbled -50bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 0.15% in 2021, then plummeted by -321bps to 0.34% in 2022, then skyrocketed by 104bps to 0.01% in 2023, then grew by 28bps to 0.02% in 2024, then tumbled by -1677bps to 0.3% in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Return on Equity are 0.3% (Q4 2025), 0.05% (Q3 2025), and 0.04% (Q2 2025).